(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 56.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Zenas Biopharma's revenue in 2025 is $15,000,000.On average, 4 Wall Street analysts forecast ZBIO's revenue for 2025 to be $2,000,239,868, with the lowest ZBIO revenue forecast at $421,103,130, and the highest ZBIO revenue forecast at $6,737,650,080. On average, 2 Wall Street analysts forecast ZBIO's revenue for 2026 to be $2,150,573,685, with the lowest ZBIO revenue forecast at $721,770,765, and the highest ZBIO revenue forecast at $3,579,376,605.
In 2027, ZBIO is forecast to generate $2,453,767,939 in revenue, with the lowest revenue forecast at $1,444,383,736 and the highest revenue forecast at $3,452,624,563.